WU Zhibing, WU Kan, LI Xiadong, JING Saisai, ZHENG Zhishuang, TANG Rongjun, LAI Jianjun, WANG Jiahao
This study aims to observe and compare the efficacy and side effect of weekly docetaxel combined with 5-fluorouracil and cisplatin intravenous treatment and weekly docetaxel plus 5-fluorouracil intravenous combined with intraperitoneal perfusion (CHPP) with cisplatin treatment. Ninety patients with advanced gastric cancer were randomized into intravenous chemotherapy group (45 patients) who received docetaxel 36 mg/m2, iv, 1wk×3wk, CF 200 mg/m2, iv, d1-5, 5-Fu 500 mg/m2, iv, d1-5, DDP 25 mg/m2, iv, d1-3, repeated every four weeks for two cycles and intravenous chemotherapy plus CHPP group (45 patients) who received docetaxel 36 mg/m2, iv, 1wk× 3wk, CF 200 mg/m2, iv, d1- 5, 5- FU 500 mg/m2, iv, d1- 5, DDP 75 mg/m2, CHPP, d1, and abdomen hyperthermia treatment with radiofrequency. The results show that all patients were assessable for response in intravenous chemotherapy group and CHPP group. The overall response rate of intravenous chemotherapy group was 44.4%. The response rate of CHPP group was 66.7%, including one CR. There was statistical difference between two groups (P=0.038). The clinical beneficial response (CBR) in intravenous chemotherapy group and CHPP group were 64.4% and 82.2%, respectively. There was apparent statistical difference (P=0.0458). The major toxicities were myelosuppression, nausea/vomiting and neurotoxicity. There was no significant difference in side effect between the two groups. Docetaxel administered by weekly infusion plus 5-fluorouracil combined with hyperthermic intraperitoneal perfusion chemotherapy with cisplatin in the treatment of advanced gastric cancer is more effective than intravenous treatment. The side effect of two groups was similar. CHPP therapy was well tolerated.
